AI-generated analysis. Always verify with the original filing.
Milestone Pharmaceuticals Inc. reported Q4 and full year 2025 financial results, including $1.5 million revenue, $63.1 million net loss, and $106.0 million cash as of December 31, 2025. The company provided updates on the CARDAMYST commercial launch following FDA approval on December 12, 2025, and received $75 million from RTW Royalty financing.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 20, 2026. 104 Cover Page Interactive Data File--the co
| Metric | Value | Basis |
|---|---|---|
| Revenue | $1.50 | |
| Research and Development Expense | $5.50 | |
| Research and Development Expense | $18.10 | |
| General and Administrative Expense | $5.10 | |
| General and Administrative Expense | $17.30 | |
| Commercial Expense | $8.20 | |
| Commercial Expense | $28.30 | |
| Net Loss | $17.40 | |
| Net Loss per Share | $0.16 | |
| Net Loss | $63.10 | |
| Net Loss per Share | $0.75 |
David Sandoval
Effective: 2026-02-10